Sign in →

Test Code LEFLU Leflunomide Metabolite (Teriflunomide), Serum

Reporting Name

Leflunomide Metabolite, S

Useful For

Therapeutic monitoring of patients actively taking leflunomide

 

Assessment of elimination in patients requiring enhanced elimination of the drug

Performing Laboratory

Mayo Medical Laboratories in Rochester

Specimen Type

Serum Red


Specimen Required


Collection Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Draw blood no sooner than 12 hours (trough value) after last dose.

2. Spin down within 2 hours of draw.


Specimen Minimum Volume

0.3 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Ambient (preferred) 28 days
  Frozen  28 days
  Refrigerated  28 days

Reference Values

Therapeutic: >40 mcg/mL

Elimination: <0.020 mcg/mL

Day(s) and Time(s) Performed

Monday, Wednesday, Friday; 4 p.m.

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

80299

LOINC Code Information

Test ID Test Order Name Order LOINC Value
LEFLU Leflunomide Metabolite, S 44828-2

 

Result ID Test Result Name Result LOINC Value
60292 Leflunomide Metabolite, S 44828-2

Clinical Information

Leflunomide is a disease-modifying antirheumatic drug approved for therapy of rheumatoid arthritis and used off-label to reduce viral nephritis in renal transplant. It is a prodrug: rapid and complete metabolism converts leflunomide to its active metabolite, teriflunomide (also called A77 1726), which acts by inhibiting pyrimidine synthesis. Teriflunomide has a very long half-life, on average >2 weeks.

 

There is marked interindividual variability in leflunomide pharmacokinetics, thus therapeutic monitoring of serum teriflunomide concentrations may be helpful in optimizing therapy. Therapeutic targets remain only loosely defined and appear to vary depending on the purpose of therapy, but serum teriflunomide concentrations >40 mcg/mL have been associated with better clinical outcomes. Due to the long half-life, serum specimens for therapeutic monitoring may be drawn at any point in the dosing cycle, although trough (immediately before next schedule dose) sampling is preferred for consistency. Adverse reactions to leflunomide do not correlate well with serum drug concentration, but include diarrhea, hypertension, and liver toxicity.

 

Enhanced elimination of the drug may be required in patients who are or who wish to become pregnant, or who are experiencing toxicity; teriflunomide can persist up to 2 years after ceasing therapy unless elimination is accelerated. This can be accomplished through use of activated charcoal or a bile acid sequestrant such as cholestyramine, reducing the half-life of teriflunomide to approximately 1 day. Serum concentrations <0.020 mcg/mL (<20 ng/mL) on 2 independent tests at least 2 weeks apart are preferred for patients anticipating pregnancy to minimize the potential risk of teratogenesis associated with the drug.

Interpretation

Therapy: clinical targets for serum teriflunomide (leflunomide metabolite) concentrations are still being determined, but levels >40 mcg/mL appear to correlate with better outcome.

 

Elimination: serum concentrations <0.020 mcg/mL (20 ng/mL) are preferred to minimize potential teratogenesis for patients considering pregnancy.

Clinical Reference

1. Cannon GW, Kremer JM: Leflunomide. Rheum Dis Clin North Am 2004;30(2):295-309

2. Chan V, Charles BG, Tett SE: Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol 2005;60(3):257-264

3. Teschner S, Gerke P, Geyer, et al: Leflunomide therapy for polyomavirus-induced allograft nephropathy: efficient BK virus elimination without increased risk of rejection. Transplant Proc 2009;41(6):2533-2538

4. Temprano KK, Bandlamudi R, Moore TL: Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005;35(2):112-121

Analytic Time

2 days

Reject Due To

Hemolysis

Mild OK; Gross OK

Lipemia

Mild OK; Gross OK

Icterus

Mild OK; Gross OK

Other

NA

Method Name

High-Turbulence Liquid Chromatography Mass Spectrometry (HTLC-MS/MS)